

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1331-222
C#/M#

Stephen D. WOLPE, et al

Group Art Unit: 1642

Serial No. 08/832,443

Examiner: Reeves

Filed: April 3, 1997

Date: July 16, 1998

Title: INHIBITOR OF STEM CELL PROLIFERATION AND
USES THEREOF

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number	
previously paid for	(at least 20) =	0 x \$ 22.00	\$ 0.00
Independent claims after amendment	0	minus highest number	
previously paid for	0 (at least 3) =	0 x \$ 82.00	\$ 0.00
If proper multiple dependent claims now added for first time, add	\$270 (ignore improper)		\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s)	\$1510 -- 4 months		\$ 1510.00
Terminal disclaimer enclosed, add	\$110		\$ 0.00
<input type="checkbox"/> Please enter the previously unentered		filed	
First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$790)		\$ 0.00
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$79)		\$ 0.00
	0	SUBTOTAL	\$ 1510.00
If "small entity," then enter half (1/2) of subtotal and subtract			-\$ 755.00
<input type="checkbox"/> Statement filed herewith			
Rule 56 Information Disclosure Statement Filing Fee (\$240)		\$ 0.00
Assignment Recording Fee (\$40.00)		\$ 0.00
		TOTAL FEE ENCLOSED	\$ 755.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 576-7400
Facsimile: (703) 576-7401
BJS:row

NIXON & VANDERHYE P.C.
By Atty. B.J. Sadoff, Reg. No. 36,663



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08/832,443	04/03/97	WOLPE	1001-2220#M#

NIXON & VANDERHYE
1100 NORTH GLEBE ROAD
8TH FLOOR
ARLINGTON VA 22201-4714

HM31/0217

DOCKETED

CLT/MATTER # 1331-222

MAIL DATE 2-17-98

DUE DATE March 17, 1998

FINAL DEADLINE August 17, 1998

DOCKETED BY Caro/jul

EXAMINER	
REEVES, J	
ART UNIT	PAPER NUMBER
1642	

DATE MAILED: 02/17/98

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

JUL 16 1998

Application No.

01/833,443

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

JUL 23 1998


Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For Rules Interpretation, call (703) 308-4215
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

08/832,443



UNITED STATES DEPARTMENT OF COMMERCE
 Patent and Trademark Office
 COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
	6

DATE MAILED:

Please find below a communication from the **EXAMINER** in charge of this application

Commissioner of Patents

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
2. Any inquiry concerning this communication should be directed to Examiner Julie E. Reeves, Ph.D, Art Unit 1642, whose telephone number is (703) 308-7553.
3. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.
4. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.
5. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be

the attached Notice to Comply with the response.

PAGE 1